It looks like nothing was found at this location. Maybe try a search?
Pages
- Career
- Cookie Policy
- Families
- Home
- Investors & Media
- Pipeline
- Pipeline
- Privacy Policy
- Terms of Use
- Who we are
- About IBT
- Families
- What we do
- Healthcare Professionals
- What is NEC?
- Contact Us
- IBT is addressing urgent medical needs in the premature infant
- IBT is developing medicines to be approved by FDA, EMA and other medicines agencies
- What is the Connection Study
Archives
- August 2023
- July 2023
- June 2023
- May 2023
- April 2023
- March 2023
- February 2023
- January 2023
- November 2022
- September 2022
- August 2022
- June 2022
- May 2022
- April 2022
- March 2022
- February 2022
- January 2022
- December 2021
- October 2021
- September 2021
- August 2021
- July 2021
- May 2021
- April 2021
- February 2021
- November 2020
- August 2020
- June 2020
- May 2020
- April 2020
- February 2020
- November 2019
- August 2019
- July 2019
- May 2019
- April 2019
- March 2019
- February 2019
- November 2018
- October 2018
- September 2018
- August 2018
- June 2018
- May 2018
- April 2018
- February 2018
- January 2018
- December 2017
- November 2017
- September 2017
- August 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- October 2015
- September 2015
- March 2015
- February 2015
- November 2014
- October 2014
- August 2014
- April 2014
- February 2014
Categories
- News (146)
- Press releases (120)
- Uncategorized (1)
Contact | [email protected]
© Copyright Infant Bacterial Therapeutics AB 2026